HC Wainwright Has Negative Forecast for TRDA Q3 Earnings

Key Points

• HC Wainwright has significantly downgraded its Q3 2025 earnings per share estimate for Entrada Therapeutics from ($1.05) to ($1.11), reflecting a pessimistic outlook for the company's financial performance.
• In a separate report, Wall Street Zen has revised Entrada Therapeutics' rating from "hold" to "sell," indicating a lack of confidence in the stock's future performance.
• Entrada's stock is currently trading at $5.19, down 2.1%, with recent earnings results showing a miss on EPS and revenue expectations, further highlighting financial struggles.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Stock analysts at HC Wainwright cut their Q3 2025 earnings estimates for shares of Entrada Therapeutics in a report released on Thursday, August 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($1.11) per share for the quarter, down from their previous forecast of ($1.05). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($3.78) EPS, Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS and FY2026 earnings at ($4.64) EPS.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.18). The company had revenue of $1.98 million for the quarter, compared to the consensus estimate of $8.17 million. Entrada Therapeutics had a negative return on equity of 17.81% and a negative net margin of 92.30%.

Separately, Wall Street Zen cut shares of Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $25.67.

Entrada Therapeutics Trading Down 3.3%

NASDAQ TRDA traded down $0.17 during trading on Monday, reaching $5.02. The company's stock had a trading volume of 242,106 shares, compared to its average volume of 217,327. The firm has a market capitalization of $190.96 million, a price-to-earnings ratio of -2.82 and a beta of -0.12. Entrada Therapeutics has a 12 month low of $4.93 and a 12 month high of $21.79. The firm has a 50 day moving average price of $6.84 and a 200 day moving average price of $8.91.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors have recently modified their holdings of the company. Intech Investment Management LLC boosted its stake in Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company's stock worth $119,000 after acquiring an additional 2,397 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company's stock valued at $4,245,000 after buying an additional 42,479 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Entrada Therapeutics by 60.6% in the second quarter. Los Angeles Capital Management LLC now owns 44,632 shares of the company's stock valued at $300,000 after purchasing an additional 16,840 shares during the last quarter. Corton Capital Inc. purchased a new stake in shares of Entrada Therapeutics in the second quarter valued at about $193,000. Finally, AlphaQuest LLC raised its holdings in shares of Entrada Therapeutics by 239.8% in the second quarter. AlphaQuest LLC now owns 39,625 shares of the company's stock valued at $266,000 after purchasing an additional 27,963 shares during the last quarter. 86.39% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Entrada Therapeutics news, Director Kush Parmar sold 75,000 shares of the company's stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $6.91, for a total value of $518,250.00. Following the completion of the transaction, the director directly owned 1,113,092 shares in the company, valued at approximately $7,691,465.72. This represents a 6.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Ventures V. L.P. 5Am sold 55,735 shares of the company's stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $6.91, for a total transaction of $385,128.85. Following the completion of the transaction, the insider owned 3,220,287 shares of the company's stock, valued at approximately $22,252,183.17. This trade represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 254,000 shares of company stock valued at $1,782,000. 7.59% of the stock is owned by corporate insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.